Apex Labs

The clinical development program of APEX focuses on supporting Veterans, a segment of the population disproportionately impacted by mental health conditions. APEX's primary clinical candidate is a low-dose synthetic psilocybin product intended for the management of Post-Traumatic Stress Disorder (PTSD) and treatment resistant depression. APEX's approach involves the creation of drug products containing Active Pharmaceutical Ingredients (API) produced through chemical synthesis, as well as drug products with API sourced from botanical origins. This diversification strategy sets APEX apart in terms of options for the development and commercialization of drug products.